Mimedx (MDXG) Cash & Equivalents (2010 - 2026)

Mimedx has disclosed Cash & Equivalents across 17 years of filings, most recently posting $135.8 million for Q2 2026.

• In Q2 2026, Cash & Equivalents rose 14.28% year-over-year to $135.8 million; the TTM figure through Jun 2026 stood at $135.8 million (up 14.28% YoY), while the FY2025 annual figure was $166.1 million, up 59.1% from the prior year.
• Cash & Equivalents came in at $135.8 million for Q2 2026 at Mimedx, down from $159.8 million in the prior quarter.
• In the past five years, Cash & Equivalents ranged from a high of $166.1 million in Q4 2025 to a low of $48.5 million in Q1 2024.
• Average Cash & Equivalents over 5 years is $96.4 million, with a median of $82.0 million recorded in 2023.
• Year-over-year, Cash & Equivalents fell 24.27% in 2022 and jumped 119.5% in 2025.
• Over 5 years, Cash & Equivalents stood at $66.0 million in 2022, then increased by 24.34% to $82.0 million in 2023, then climbed by 27.34% to $104.4 million in 2024, then jumped by 59.1% to $166.1 million in 2025, then retreated by 18.23% to $135.8 million in 2026.
• Per Business Quant data, the three most recent Cash & Equivalents figures were $135.8 million in Q2 2026, $159.8 million in Q1 2026, and $166.1 million in Q4 2025.